---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-021937"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:34:51.578122+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma sells PRV for $105M, draws $20M from Hercules; cash runway extended into late 2025

## Summary
- Sold Rare Pediatric Disease Priority Review Voucher for $105M cash; buyer undisclosed.
- Drew additional $20M tranche under existing Hercules Capital term loan facility (interest-only until July 2027).
- Combined with $82M cash at March 31, 2024, total pro-forma cash ~$207M; runway extended into late 2025, excluding XOLREMDI sales.
- CFO Adam Mostafa awarded $102K discretionary bonus for efforts in securing the PRV sale.
- XOLREMDI (mavorixafor) received FDA approval in April 2024 for WHIM syndrome; Phase 3 trial in chronic neutropenia planned this quarter.

## SEC filing metadata
- accession: 0001628280-24-021937
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/xfor-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-021937
- JSON: https://secwatch.observer/filing/0001628280-24-021937.json
- Plain text: https://secwatch.observer/filing/0001628280-24-021937.txt

## Key facts
- M&A Transactions
  X4 Pharmaceuticals, Inc completed a disposition for $105.0 million (closed 2024-05-08).
  - Action: disposition
  - Consideration: $105.0 million
  - Closing: 2024-05-08
  source text: On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm
- Material Agreements
  X4 Pharmaceuticals, Inc entered into Asset Purchase Agreement with not specified valued at $105,000,000 (effective 2024-05-08).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: not specified
  - Value: $105,000,000
  - Effective: 2024-05-08
  source text: On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.